Pfizer Inc acquires Global Blood Therapeutics, Inc. (2022)

Deal facts

Buyer: Pfizer Inc
Target: Global Blood Therapeutics, Inc.
Deal value: Not disclosed
Announced: 8 August 2022
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

5 Oct 2022CompletedClosed
Pfizer Inc completes acquisition of Global Blood Therapeutics, Inc.
Introductory Note. On October 5, 2022 (the “ Closing Date ”), Global Blood Therapeutics, Inc., a Delaware corporation (“ GBT ”, the “ Company ”, “ we ”, “ our ” or “ us ”), completed the previously announced merger of Ribeye Acquisition Corp., a Delaware corporation (“ Merger Sub ”) and a wholly owned subsidiary of Pfizer Inc., a Delaware corporation (“ Parent ”), with and into GBT (the “ Merger ”
Source

OpinionExit Mode editorial

We see a clear signal in the Pfizer acquisition of Global Blood Therapeutics, announced on 8 August 2022. This completed deal, structured as a going-private transaction, involved a cash-only consideration. The absence of any public figure for the deal value in the records does not obscure the strategic intent. A major US pharmaceutical house is absorbing a specialist biotech firm to secure a specific asset. For the SME founder reading this, the mechanism is straightforward: a large buyer pays cash to take a company off the public market. This removes the volatility of public listing and the constant pressure to deliver quarterly results, replacing it with the resources of a global entity.

The decision to move the target from public to private ownership via a cash deal suggests the buyer values control and speed over the transparency of a public market listing. In the healthcare sector, this often means the acquirer needs to integrate complex intellectual property or clinical pipelines without the distraction of public scrutiny during the critical development phase. While the JSON does not list specific regulatory hurdles, such a cross-border or domestic US deal in this sector invariably triggers competition reviews. The buyer must navigate the US antitrust framework to ensure the acquisition does not stifle market competition. This process can delay completion or force divestitures, yet the all-cash nature of the offer indicates the buyer is prepared to absorb these costs and risks to secure the asset.

We view this as a definitive exit route for founders who have built a company to a stage where public markets no longer serve the long-term strategy. The cash component eliminates share-price risk for the selling shareholders, providing immediate liquidity. However, it also means the founder and early investors must accept a fixed price rather than participating in future upside through equity. The deal type confirms that the target company likely possessed a technology or product line that fit neatly into the buyer's existing portfolio, making the integration path clear. The lack of an earn-out structure in the consideration type implies the buyer saw the value as certain and immediate.

For the founder planning an exit this week, your immediate task is to audit your own capital structure against the cash-only model. Determine if your current valuation relies on future growth stories that public markets might penalise, or if your value is locked in tangible assets that a strategic buyer would pay cash for today.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2022 deals More going private deals More from Pfizer Inc All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history

Pfizer Inc

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive

Pfizer Inc to acquire Global Blood Therapeutics, Inc.

Deal facts

Join Exit Mode Insider

Deal timeline

Browse adjacent archives

Similar deals

Merck to acquire Terns Pharmaceuticals, Inc.

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

Servier to acquire Day One Biopharmaceuticals, Inc.

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Abbott to acquire Exact Sciences Corp

Pfizer Inc

How this page is built